These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9285120)

  • 1. Transforming growth factor-beta in breast cancer: a working hypothesis.
    Reiss M; Barcellos-Hoff MH
    Breast Cancer Res Treat; 1997 Aug; 45(1):81-95. PubMed ID: 9285120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta.
    Dumont N; Arteaga CL
    Breast Cancer Res; 2000; 2(2):125-32. PubMed ID: 11250702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta in cancer and metastasis.
    Jakowlew SB
    Cancer Metastasis Rev; 2006 Sep; 25(3):435-57. PubMed ID: 16951986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.
    Barrack ER
    Prostate; 1997 Apr; 31(1):61-70. PubMed ID: 9108888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta and cancer: a love-hate relationship?
    Reiss M
    Oncol Res; 1997; 9(9):447-57. PubMed ID: 9495450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
    Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells.
    Frey RS; Mulder KM
    Cancer Res; 1997 Feb; 57(4):628-33. PubMed ID: 9044838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells.
    Koli K; Keski-Oja J
    Cancer Res; 1995 Apr; 55(7):1540-6. PubMed ID: 7882362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
    Yoo YA; Kim YH; Kim JS; Seo JH
    Biochim Biophys Acta; 2008 Mar; 1783(3):438-47. PubMed ID: 18164268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1.
    Ji H; Stout LE; Zhang Q; Zhang R; Leung HT; Leung BS
    J Cell Biochem; 1994 Mar; 54(3):332-42. PubMed ID: 8200913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
    Wilson CA; Cajulis EE; Green JL; Olsen TM; Chung YA; Damore MA; Dering J; Calzone FJ; Slamon DJ
    Breast Cancer Res; 2005; 7(6):R1058-79. PubMed ID: 16457687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor beta secretion from primary breast cancer fibroblasts.
    van Roozendaal CE; Klijn JG; van Ooijen B; Claassen C; Eggermont AM; Henzen-Logmans SC; Foekens JA
    Mol Cell Endocrinol; 1995 Apr; 111(1):1-6. PubMed ID: 7649348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
    Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
    Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth.
    Herman ME; Katzenellenbogen BS
    Cancer Res; 1994 Nov; 54(22):5867-74. PubMed ID: 7954416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta and breast cancer: Mammary gland development.
    Barcellos-Hoff MH; Ewan KB
    Breast Cancer Res; 2000; 2(2):92-9. PubMed ID: 11250698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.
    Heldin NE; Bergström D; Hermansson A; Bergenstråhle A; Nakao A; Westermark B; ten Dijke P
    Mol Cell Endocrinol; 1999 Jul; 153(1-2):79-90. PubMed ID: 10459856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.
    Butta A; MacLennan K; Flanders KC; Sacks NP; Smith I; McKinna A; Dowsett M; Wakefield LM; Sporn MB; Baum M
    Cancer Res; 1992 Aug; 52(15):4261-4. PubMed ID: 1322240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.